secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0000950170-23-009483
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma reports FY2022 net loss of $95.6M ($2.53/sh); cash $245.2M; $10M legal settlement
--------------------------------------------------------------------------------

- Net loss $95.6M ($2.53 EPS) vs $54.9M ($1.49 EPS) in 2021; R&D spend rose 44% to $61.5M.
- Cash, equivalents and investments $245.2M at Dec 31, 2022, vs $319.7M year earlier.
- Recorded $10M legal settlement expense for securities class action; subject to court approval.
- Targeting LIFT-AD Phase 2/3 enrollment completion mid-2023, topline data early 2024.
- ATH-1105 (ALS) IND-enabling studies ongoing; Phase 1 expected in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017023009483/0000950170-23-009483-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017023009483/atha-20230323.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009483

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer